ReviewAdvances in therapy2023
Desmoid Tumors: A Comprehensive Review.
Review in Advances in therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 78 citations in OpenAlex.
- Phase III Trial of Pegylated Liposomal Doxorubicin for Patients with Advanced and Refractory Desmoid Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Abnormal Presentation of an Intra-abdominal Desmoid Tumor in a Young, Healthy Male: A Case Report.Cureus · 2026Article
- Obstructive Pyelonephritis Secondary to Ureteral Compression by an Intra-Abdominal Desmoid Tumor in Familial Adenomatous Polyposis: A Case Report.Clinical case reports · 2026Article
- Expert opinion document on the management of desmoid tumours in adult patients in Spain.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Desmoid tumour of the rectus sheath following myomectomy: a mimicker of parasitic leiomyoma.Journal of surgical case reports · 2026Article
- Recurrent Desmoid-Type Fibromatosis of the Breast in a Young Woman With a Monoallelic MUTYH Germline Variant.Cureus · 2026Article
- Axillary desmoid-type fibromatosis: a rare clinical presentation, histopathological correlation, and literature review.BMC surgery · 2026Review
- Impact of Anatomical Localization on Systemic Inflammatory Markers and Immune Checkpoint CD47 in Desmoid Tumors.Journal of clinical medicine · 2026Article
- Systemic Therapies for Desmoid Tumors: A Review of Past, Present, and Future Treatments.Cancers · 2026Review
- Article
- Real-World Characterization and Treatment Patterns of Patients with Desmoid Tumors at an Academic Center in the United States.Cancer research communications · 2026Article
- Abdominal wall desmoid tumor postcesarean section: A case report.Radiology case reports · 2026Article
- Article
- The Health-Related Quality of Life of German Desmoid Patients: Results from the PROSa-DES and PROSa Study.Cancers · 2026Article
- Successful Pregnancy and Delivery Following Autologous Abdominal Wall Reconstruction: A Case Report and Literature Review.Plastic and reconstructive surgery. Global open · 2026Article
- Breast Fibromatosis in a Patient With a History of Treated Breast Cancer: A Case Report.Clinical case reports · 2026Article
- Genotype-guided conservative management of mesenteric desmoid tumors: A case report of intermediate-region APC mutations.Medicine · 2026Article
- Intra-Oral Aggressive Fibromatosis: A Systematic Review of Case Reports and Case Series.Journal of clinical medicine · 2026Review
- Evaluating the impact of surgical resection on desmoid tumour growth: a retrospective analysis from the National Cancer Centre Singapore.Frontiers in surgery · 2026Article
- Application value of image-guided radiotherapy in reducing setup errors of head and neck tumors: a retrospective study.American journal of translational research · 2026Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Desmoid tumors (DT) are rare, locally aggressive, fibroblastic soft-tissue tumors that are characterized by infiltrative growth and can affect organs and adjacent structures, resulting in substantial clinical burden impacting patients' health-related quality of life. Searches of PubMed, Embase, Cochrane, and key conferences were conducted in November 2021 and updated periodically through March 2023 to identify articles describing the burden of DT. Of 651 publications identified, 96 relevant ones were retained. Diagnosis of DT is challenging because of its morphologic heterogeneity and variable clinical presentation. Patients visit multiple healthcare providers, often facing delays in correct diagnosis. The low incidence of DT (estimated 3-5 cases per million person-years) limits disease awareness. Patients with DT experience a high symptom burden: up to 63% of patients experience chronic pain, which leads to sleep disturbance (73% of cases), irritability (46% of cases), and anxiety/depression (15% of cases). Frequently mentioned symptoms are pain, limited function and mobility, fatigue, muscle weakness, and swelling around the tumor. Overall, quality of life in patients with DT is lower than in healthy controls. There is no treatment approved by the US Food and Drug Administration for DT; however, treatment guidelines reference available options, such as active surveillance, surgery, systemic therapy, and locoregional therapy. Choice of active treatment may depend on tumor location, symptoms, and risk of morbidity. The substantial burden of illness of DT is related to difficulties in timely and accurate diagnosis, high symptom burden (pain and functional limitations), and decreased quality of life. There is a high unmet need for treatments that specifically target DT and improve quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.